Ascendis Pharma A/S
ASND
$165.72
$1.070.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.05% | 21.61% | -24.89% | 189.00% | 533.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.05% | 21.61% | -24.89% | 189.00% | 533.69% |
| Cost of Revenue | -28.64% | 53.14% | -12.31% | 65.81% | 301.04% |
| Gross Profit | 33.89% | 15.88% | -29.61% | 208.65% | 600.57% |
| SG&A Expenses | 24.15% | 10.88% | 4.55% | 1.60% | 19.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.43% | -14.42% | -11.09% | -17.18% | 7.86% |
| Operating Income | 101.04% | 27.30% | 6.44% | 65.38% | 73.83% |
| Income Before Tax | 54.35% | 38.63% | 11.43% | -18.69% | 57.72% |
| Income Tax Expenses | -81.45% | 59.74% | 152.78% | 95.74% | 14.05% |
| Earnings from Continuing Operations | 56.16% | 38.24% | 10.93% | -19.59% | 55.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.16% | 38.24% | 10.93% | -19.59% | 55.87% |
| EBIT | 101.04% | 27.30% | 6.44% | 65.38% | 73.83% |
| EBITDA | 104.58% | 28.05% | 6.43% | 67.50% | 74.75% |
| EPS Basic | 58.52% | 39.59% | 12.68% | -17.93% | 56.35% |
| Normalized Basic EPS | 56.82% | 39.97% | 13.18% | -17.04% | 58.18% |
| EPS Diluted | 58.52% | 39.59% | 12.68% | -17.93% | 56.35% |
| Normalized Diluted EPS | 56.82% | 39.97% | 13.18% | -17.04% | 58.18% |
| Average Basic Shares Outstanding | 5.70% | 2.24% | 2.01% | 1.41% | 1.11% |
| Average Diluted Shares Outstanding | 5.70% | 2.24% | 2.01% | 1.41% | 1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
